Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Telomir Pharmaceuticals Inc (TELO)

$1.29 0.00 (N/A)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	88.72M
Revenue (ttm)	0.00
Net Income (ttm)	-10.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.04

Volume	77,500
Avg Vol	145,684
Day's Range	N/A - N/A
Shares Out	68.78M
Stochastic %K	69%
Beta	-0.21
Analysts	Strong Buy
Price Target	$15.50

Company Profile

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Proge...

Industry: Biotechnology

Sector: Healthcare

Phone: 786 396 6723

Website: telomirpharma.com

Address:

100 SE 2nd Street, Suite 2000 #1009, Miami, United States

Tristan2024 May. 27 at 1:43 PM

$TELO https://x.com/telomirpharma/status/2059630955099263235?s=46

0 · Reply

Tristan2024 May. 26 at 7:44 PM

$TELO $8+ EOW

0 · Reply

Daddydoyouright May. 22 at 11:02 PM

$TELO man this stock needs to pick up

1 · Reply

Tristan2024 May. 22 at 5:12 PM

$TELO $8+

0 · Reply

MilsLearning May. 22 at 9:40 AM

$TELO

0 · Reply

MarketAttack May. 22 at 8:03 AM

$TELO fly high dude

0 · Reply

DARKP00L May. 20 at 12:11 PM

$TELO 08:04 on May. 20 2026 Telomir Pharma Announces Peer-Reviewed Publication Of Preclinical Data Showing Telomir-Zn Produced Dose-Dependent Survival Improvement Across Multiple Endpoints In Wilson's Disease Model #tradeideas

0 · Reply

Tristan2024 May. 20 at 10:46 AM

$TELO $8+ on news.

0 · Reply

MarketAttack May. 20 at 8:44 AM

$TELO one of the best oversold...soon 4$

0 · Reply

Washingtonstate May. 19 at 2:56 PM

$TELO buying opportunity 🍀🥳

0 · Reply

Telomir Pharmaceuticals reports peer-reviewed publication of data on Telomir-Zn

May 20, 2026, 8:00 AM EDT - 7 days ago

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

Telomir announces U.S. FDA cleared IND application for Telomir-Zn

2026-04-30T15:55:48.000Z - 26 days ago

Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer

Telomir Pharmaceuticals announces in vitro data on Telomir-1

2026-02-17T13:46:33.000Z - 3 months ago

Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models

2025-12-18T12:45:18.000Z - 5 months ago

Telomir Pharmaceuticals reports results from safety studies for Telomir-1

Dec 18, 2025, 7:30 AM EST - 5 months ago

Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development

2025-11-25T13:15:14.000Z - 6 months ago

Telomir Pharmaceuticals announces new preclinical data on Telomir-1

Nov 25, 2025, 8:00 AM EST - 6 months ago

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells

2025-11-21T12:35:19.000Z - 6 months ago

Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line

2025-10-23T11:45:22.000Z - 7 months ago

Telomir says data shows Telomir-1 resets cancer ‘kill-and-clean’ defense system

Oct 23, 2025, 7:30 AM EDT - 7 months ago

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo

2025-10-21T11:45:13.000Z - 7 months ago

Telomir Pharmaceuticals executes binding LOI to acquire TELI Pharmaceuticals

Oct 21, 2025, 7:30 AM EDT - 7 months ago

Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth

2025-10-14T12:41:32.000Z - 8 months ago

Telomir Pharmaceuticals announces new laboratory findings on Telomir-1

Oct 14, 2025, 8:00 AM EDT - 8 months ago

Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer

2025-10-09T11:40:49.000Z - 8 months ago

Telomir says Telomir-1 selectively kills agressive TNBC cells

Oct 9, 2025, 7:30 AM EDT - 8 months ago

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells

2025-10-07T11:40:23.000Z - 8 months ago

Telomir Pharmaceuticals announces new findings in prostate cancer model

Oct 7, 2025, 7:30 AM EDT - 8 months ago

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance

2025-09-18T12:30:34.000Z - 8 months ago

Telomir Pharmaceuticals announces in vitro data on Telomir-1

Sep 18, 2025, 8:00 AM EDT - 8 months ago

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies

2025-09-09T12:30:34.000Z - 9 months ago

Telomir Pharmaceuticals announces preclinical cancer data on Telomir-1

Sep 9, 2025, 8:00 AM EDT - 9 months ago

Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy

Aug 28, 2025, 8:00 AM EDT - 9 months ago

Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction

Jul 24, 2025, 8:00 AM EDT - 10 months ago

Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's

Jul 18, 2025, 8:00 AM EDT - 11 months ago

Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin

Jun 18, 2025, 9:15 AM EDT - 1 year ago

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

Jun 11, 2025, 9:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model

Jun 5, 2025, 8:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome

Jun 2, 2025, 8:30 AM EDT - 1 year ago

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform

May 29, 2025, 8:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints

May 21, 2025, 9:00 AM EDT - 1 year ago

Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND

May 15, 2025, 8:00 AM EDT - 1 year ago

Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity

May 7, 2025, 8:00 AM EDT - 1 year ago

Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells

Feb 26, 2025, 8:00 AM EST - 1 year ago

Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines

Feb 21, 2025, 8:00 AM EST - 1 year ago

Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market

Feb 18, 2025, 8:00 AM EST - 1 year ago

Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)

Jan 28, 2025, 8:00 AM EST - 1 year ago

Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses

Jan 7, 2025, 8:00 AM EST - 1 year ago

Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)

Dec 23, 2024, 7:30 AM EST - 1 year ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

Dec 12, 2024, 8:30 AM EST - 1 year ago

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

Dec 3, 2024, 7:30 AM EST - 1 year ago

Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1

Nov 21, 2024, 7:00 AM EST - 1 year ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

Sep 26, 2024, 4:00 PM EDT - 1 year ago

Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs

Aug 20, 2024, 7:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

May 30, 2024, 8:30 AM EDT - 2 years ago

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

Apr 16, 2024, 8:30 AM EDT - 2 years ago

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

Apr 2, 2024, 8:30 AM EDT - 2 years ago

Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Mar 29, 2024, 4:44 PM EDT - 2 years ago

UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Tristan2024 May. 27 at 1:43 PM

$TELO https://x.com/telomirpharma/status/2059630955099263235?s=46

0 · Reply

Tristan2024 May. 26 at 7:44 PM

$TELO $8+ EOW

0 · Reply

Daddydoyouright May. 22 at 11:02 PM

$TELO man this stock needs to pick up

1 · Reply

Tristan2024 May. 22 at 5:12 PM

$TELO $8+

0 · Reply

MilsLearning May. 22 at 9:40 AM

$TELO

0 · Reply

MarketAttack May. 22 at 8:03 AM

$TELO fly high dude

0 · Reply

DARKP00L May. 20 at 12:11 PM

0 · Reply

Tristan2024 May. 20 at 10:46 AM

$TELO $8+ on news.

0 · Reply

MarketAttack May. 20 at 8:44 AM

$TELO one of the best oversold...soon 4$

0 · Reply

Washingtonstate May. 19 at 2:56 PM

$TELO buying opportunity 🍀🥳

0 · Reply

PF_Goodrich May. 14 at 1:05 PM

$TELO i would get excited about a 9 cent move pre-market but its based on a whopping 450 shares. i could be a real market mover if i wanted to lol

1 · Reply

PF_Goodrich May. 12 at 6:03 PM

$TELO tempted to buy more at this price but I already bought a bunch at 1.28

0 · Reply

Tristan2024 May. 12 at 12:28 PM

$TELO 🚀🚀🚀

0 · Reply

MarketAttack May. 11 at 6:28 AM

$TELO do it and surprise everyone

0 · Reply

MarketAttack May. 11 at 6:28 AM

$TELO not regretted buying it for a second

0 · Reply

MarketAttack May. 11 at 6:28 AM

$TELO we will do it...one of a kind drug

0 · Reply

MarketAttack May. 11 at 6:27 AM

$TELO 2.5>4>6.4>8$

0 · Reply

MarketAttack May. 11 at 6:27 AM

$TELO never lost hope in that

0 · Reply

MarketAttack May. 11 at 6:26 AM

$TELO news pending...watch the next jump to 2$

1 · Reply

Washingtonstate May. 9 at 1:46 AM

$TELO

1 · Reply

PF_Goodrich May. 7 at 3:15 PM

$TELO come down to papa. my position is at 1.33 and im looking to build

0 · Reply

Tristan2024 May. 7 at 11:25 AM

$TELO news this morning

0 · Reply

1.0.0